Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Blood

Volumn 118, Issue 8, 2011, Pages 2062-2068

  Parikh, Sameer A ^a   Keating, Michael J ^a   O'Brien, Susan ^a   Wang, Xuemei ^a   Ferrajoli, Alessandra ^a   Faderl, Stefan ^a   Burger, Jan ^a   Koller, Charles ^a   Estrov, Zeev ^a   Badoux, Xavier ^a   Lerner, Susan ^a   Wierda, William G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; BETA 2 MICROGLOBULIN; CIDOFOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; HYDROCORTISONE; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULITIS; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLOSTRIDIUM DIFFICILE INFECTION; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HIGH RISK PATIENT; HISTOPLASMOSIS; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORAXELLACEAE INFECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PARAINFLUENZA VIRUS INFECTION; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSEUDOMONAS INFECTION; SEPSIS; SEPTIC SHOCK; SINUSITIS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 80052180048     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329177     Document Type: Article

References (21)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
2. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
4. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23(28): 7024-7031.
5. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561. (Pubitemid 34534522)
6. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99(6):2245-2247. (Pubitemid 34525514)
7. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20(18):3891-3897.
8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
9. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol. 1996;14(1): 296-303. (Pubitemid 26020026)
10. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008; 113(8):2110-2118.
11. Faderl S, WierdaW, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 years. Leuk Res. 2010;34(3):284-8.
12. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27(27):4578-4584.
13. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in firstline therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 205.
14. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(4):498-503.
15. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109(2):405-411. (Pubitemid 46105933)
16. Zenz T, Hoth P, Busch R, et al. TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 1267.
17. Delgado J, Milligan DW, Dreger P. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood. 2009;114(13):2581-2588.
18. Hallam S, Gribben JG. Transplantation in chronic lymphocytic leukemia: timing and expectations. Clin Lymphoma Myeloma. 2009;9(suppl 3):S186-S193.
19. Kwok M, Rawstron AC, Varghese A, Hillmen P. Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 540.
20. Sayala HA, Rawstron AC, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2007;20(3):499-512. (Pubitemid 47250498)
21. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009;27(10):1637-1643.